A Five-Grain Powder for Assisting in Lowering Blood Pressure and Its Preparation Method

By scientifically combining dietary fiber, resistant starch, prebiotics, and food-medicine homologous components, and optimizing the preparation process, the shortcomings of existing five-grain powder formulas and processes have been overcome, achieving a synergistic effect of intestinal flora regulation and blood pressure regulation, and improving the antihypertensive effect and long-term efficacy.

CN123100840APending Publication Date: 2026-11-17SHANDONG TIANJIU BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611348401.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-02
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing formulas for blood pressure-lowering multigrain powders lack synergy, fail to address gut microbiota regulation, and employ crude preparation processes that result in poor dissolution of active ingredients, leading to limited blood pressure-lowering effects and poor long-term efficacy.

Method used

It employs a scientific combination of dietary fiber, resistant starch, prebiotics, food and medicine homology, and functional fortification groups, combined with low-temperature fermentation, ultra-fine grinding, and vacuum freeze-drying processes to precisely control particle size and pH value, thereby achieving efficient colonization of probiotics and full dissolution of active ingredients.

Benefits of technology

It achieves regulation of gut microbiota structure and long-term control of blood pressure, significantly improving the antihypertensive effect and long-term effectiveness, and ensuring the efficient absorption and retention of active ingredients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100840A_ABST
    Figure CN123100840A_ABST
Patent Text Reader

Abstract

This invention discloses a blood pressure-lowering multigrain powder and its preparation method, relating to the technical field of blood pressure-lowering multigrain powders. The method includes the following steps: S1: Mixing a dietary fiber group, a resistant starch group, a prebiotic group, a food-medicine homology group, and a functional enhancement group; S2: Mixing the dietary fiber group and the resistant starch group obtained in step S1 evenly; S3: Ultra-finely pulverizing the fermentation base obtained in step S2, the food-medicine homology group obtained in step S1, and the functional enhancement group; S4: Adding the pulverized food-medicine homology group and the functional enhancement group to the pulverized fermentation base; S5: Sterilizing and packaging the mixed powder obtained in step S4. This invention, through the synergistic effect of the dietary fiber group, resistant starch group, prebiotic group, food-medicine homology group, and functional enhancement group, achieves a more significant and longer-lasting blood pressure-lowering effect compared to existing single-component products, solving the problem of existing products having a single blood pressure-lowering mechanism and diminishing effects with long-term consumption.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of blood pressure lowering grain powder technology, and in particular to a blood pressure lowering auxiliary grain powder and its preparation method. Background Technology

[0002] Hypertension is a prevalent chronic cardiovascular disease worldwide. Long-term high blood pressure can easily lead to complications in multiple organs, including the heart, brain, and kidneys, seriously threatening human health. Currently, the management of hypertension mainly relies on a combination of drug treatment and dietary intervention. Among these methods, whole grain powders, which are considered both food and medicine, have become an important choice for daily dietary intervention for people with hypertension due to their mild taste, convenient consumption, and lack of obvious side effects.

[0003] In existing technologies, the preparation of multigrain powder for assisting in lowering blood pressure mostly adopts conventional processes. It mainly uses whole grains such as oats, brown rice, and mixed beans as basic raw materials, combined with medicinal and edible ingredients such as hawthorn, cassia seed, and kudzu root. It is made through simple processes such as crushing, mixing, and drying. Its core mechanism of action is mainly concentrated on using substances such as flavonoids and anthraquinones in medicinal and edible ingredients to directly dilate blood vessels and regulate angiotensin, thereby achieving the effect of assisting in lowering blood pressure.

[0004] However, existing blood pressure-lowering multigrain powders lack synergy in their formulations, often consisting of simple additives of single ingredients. They fail to consider the role of gut microbiota in regulating blood pressure and neglect the synergistic effects between dietary fiber, resistant starch, prebiotics, and probiotics. Dietary fiber and resistant starch provide carbon sources for beneficial gut bacteria, prebiotics promote their proliferation, and probiotics directly regulate the balance of the gut microbiota. Existing formulations do not scientifically combine these components, resulting in limited blood pressure-lowering effects and poor long-term efficacy, failing to achieve the dual synergistic effects of gut regulation and direct blood pressure reduction. Furthermore, existing preparation processes are crude, with conventional pulverization resulting in coarse particle sizes that are difficult to fully dissolve active ingredients, leading to poor absorption efficiency. High-temperature drying and single fermentation processes can easily destroy the active ingredients in the raw materials (such as anthocyanins, flavonoids, and probiotic activity), not only reducing the product's efficacy and nutritional value but also causing low probiotic proliferation efficiency, failing to fully leverage the auxiliary blood pressure-lowering effect of gut microbiota regulation, and further weakening the product's actual conditioning effect.

[0005] With the increasing demands for dietary therapy for hypertension and the deepening research on the relationship between gut microbiota and blood pressure, there is an urgent need for a multigrain powder and its preparation method that can achieve synergistic effects through scientifically matched components, optimize the preparation process to retain active ingredients and improve absorption efficiency, and then achieve highly effective blood pressure reduction by regulating gut microbiota, in order to solve the above-mentioned defects of existing technologies. Summary of the Invention

[0006] The purpose of this invention is to provide a five-grain powder for assisting in lowering blood pressure and its preparation method, so as to solve the problems mentioned in the background art.

[0007] To achieve the above objectives, the present invention provides the following technical solution: a method for preparing a multigrain powder for assisting in lowering blood pressure, comprising the following steps: S1: The dietary fiber group, resistant starch group, prebiotic group, food-medicine homology group, functional fortification group, and other powdered compositions are formulated according to the following weight percentages: dietary fiber group 35-50%, resistant starch group 25-35%, prebiotic group 8-15%, food-medicine homology group 5-12%, and functional fortification group 2-5%; wherein, the dietary fiber group is composed of purple potato flour and oat bran, with a weight ratio of (2-4):1; the resistant starch group is composed of high-resistant starch brown rice and mixed beans, with a weight ratio of (2-4):1. The weight ratio is (1.5-2.5):1; the prebiotic group consists of xylooligosaccharides, inulin and resistant dextrin, with a weight ratio of (3-5):(2-3):(1-2); the food-medicine homology group consists of hawthorn extract, poria cocos powder and cassia seed extract, with a weight ratio of (3-4):(2-3):1; the functional enhancement group consists of buckwheat flavonoids and mulberry leaf DNJ in a weight ratio of (1-3):1; and the weight ratio of dietary fiber group to resistant starch group is (1.2-1.8):1. S2: Mix the dietary fiber group and resistant starch group obtained in step S1 evenly, adjust the moisture content to 25-30%, inoculate with compound probiotics, and carry out low-temperature fermentation at 26℃-32℃ and dissolved oxygen ≤2mg / L to obtain fermentation substrate; S3: The fermentation substrate obtained in step S2, the food-medicine homology group and the functional enhancement group obtained in step S1 are subjected to ultra-fine grinding, and the particle size D50 of the fermentation substrate is controlled to be 20μm-25μm, the particle size D50 of the food-medicine homology group is 10μm-15μm, and the particle size D50 of the functional enhancement group is ≤10μm. S4: First, add the pulverized medicinal and edible homologous group and functional enhancement group to the pulverized fermentation base material, and mix for 10-15 minutes at a speed of 20-40 rpm and a temperature ≤25℃ to obtain a primary mixture; then add the prebiotic group obtained in step S1 to the primary mixture, and mix for 5-10 minutes at a speed of 10-20 rpm and a temperature ≤20℃ to obtain a mixed powder; wherein, the amount of inulin added is increased by 15-25% according to the ratio in step S1; S5: After sterilizing the mixed powder obtained in step S4, package it to obtain the blood pressure lowering five-grain powder.

[0008] Preferably, in step S1, the purple potato flour contains anthocyanin content ≥200mg / 100g, the oat bran contains β-glucan content ≥10%, the high-resistant starch brown rice contains resistant starch content ≥15%, the mixed beans are at least one of black beans and chickpeas, the hawthorn extract contains total flavonoid content ≥10%, the poria cocos powder contains polysaccharide content ≥30%, the cassia seed extract contains total anthraquinone content ≤0.5%, and the other powdered compositions in step S1 include black bean flour, soybean flour, walnut flour, millet flour, corn flour, and enzymatically hydrolyzed oat flour.

[0009] Preferably, the low-temperature fermentation in step S2 employs a three-stage temperature-controlled fermentation process, and the pH is adjusted by controlling the aeration rate and feeding rate. The first phase is the activation period, with a temperature of 28℃-30℃, a duration of 4-6 hours, a ventilation rate of 0.5 vvm-1.0 vvm, and the pH controlled to drop to 5.5-6.0. The second stage is the proliferation period, with a temperature of 30℃-32℃, a duration of 6h-12h, a ventilation rate reduced to 0.1vvm-0.3vvm, and a pH controlled to 4.8-5.2. The third stage is the stabilization period, with a temperature of 26℃-28℃ and a time of 2h-6h. Aeration is stopped, and the final pH is controlled at 4.5-5.0. The total fermentation time is 12h-24h.

[0010] Preferably, the compound probiotics in step S2 are composed of Lactobacillus plantarum, Lactobacillus acidophilus and Bifidobacterium lactis in a live bacteria ratio of (2-3):(1-2):1.

[0011] Preferably, the fermentation substrate in step S3 is first subjected to vacuum freeze-drying before ultrafine pulverization: dried to a moisture content of ≤8% at -40℃ to -50℃ and a vacuum degree of ≤10Pa, and then transferred to an air jet mill within 5 minutes for ultrafine pulverization under low temperature inert gas protection at 0℃ to 5℃, controlling the particle size D50 to be 20μm to 25μm; the ultrafine pulverization of the medicinal and edible homologous group in step S3 adopts liquid nitrogen freeze pulverization process, with a pulverization temperature of ≤-40℃.

[0012] Preferably, in step S4, the medicinal and edible homology group and the functional enhancement group are premixed for 3-10 minutes before adding the fermentation base to obtain a medicinal and edible functional premix, and then the fermentation base is added. The prebiotic component in step S4 is added in two stages: In the first stage, xylooligosaccharides and resistant dextrin are added to the primary mixture and mixed for 3-5 minutes at a speed of 15-25 rpm and a temperature of ≤22℃ to obtain the intermediate mixture. In the second stage, inulin is added to the intermediate mixture and mixed for 2-5 minutes at a speed of 10-20 rpm and a temperature of ≤20℃. The inulin is added in equal amounts in two stages after the proportion of inulin is increased by 15-25% in step S1.

[0013] Preferably, when used to prepare five-grain powder for salt-sensitive hypertension, in step S1, an additional 2-3% of a low-sodium salt substitute composed of potassium chloride and ammonium chloride in a weight ratio of 2:1 is added, and the proportion of Poria cocos powder in the food-medicine homology group is increased to 40-50%; in step S2, the proliferation period is extended to 10-12 hours.

[0014] Preferably, when used to prepare whole grain powder for obesity-related hypertension, 3-5% konjac glucomannan is added in step S1, and the proportion of resistant starch is increased to 32-35%; in step S3, konjac glucomannan and fermentation base are pulverized together to a D50 of 30μm-40μm.

[0015] Preferably, when used to prepare a multigrain powder for treating isolated systolic hypertension in the elderly, in step S1, the proportion of xylooligosaccharides in the prebiotic group is increased to 50-60%, and vitamin K2 40-60μg / 100g powder is added additionally; in step S4, the addition is carried out in stages, first 50% of xylooligosaccharides are mixed with the primary mixture, and the remaining 50% is added together with inulin during the second stage of prebiotic addition.

[0016] A type of whole grain powder for assisting in lowering blood pressure, prepared by a specific method; the whole grain powder contains anthocyanins ≥100mg / 100g, β-glucan ≥5%, and a GI value ≤55.

[0017] The technical effects and advantages of this invention are as follows: (1) This invention utilizes the combined effects of dietary fiber, resistant starch, prebiotics, food and medicine homology, and functional enhancement groups. The dietary fiber and resistant starch groups provide sufficient carbon sources for beneficial bacteria in the gut, while the prebiotics precisely promote the proliferation of beneficial bacteria such as Bifidobacterium and Lactobacillus plantarum. The compound probiotics are scientifically fermented and efficiently colonize the gut, jointly regulating the gut microbiota structure and increasing the production of short-chain fatty acids, thereby achieving long-term blood pressure regulation from the root. At the same time, the food and medicine homology group and the functional enhancement group work synergistically. The total flavonoids, polysaccharides, and other active ingredients contained in the group directly act on vascular regulation and metabolic pathways, enhancing the auxiliary blood pressure lowering effect. Compared with existing single-ingredient products, the blood pressure lowering effect is more significant and the long-term effect is stronger, solving the problem of the single blood pressure lowering mechanism and the decay of the effect after long-term consumption of existing products. (2) This invention employs vacuum freeze-drying and low-temperature inert gas protection for ultra-fine pulverization of fermentation base materials, and liquid nitrogen freeze-pulverization for the medicinal and edible homology group and the functional enhancement group. The entire process is carried out in a low-temperature environment to prevent the destruction of heat-sensitive components such as anthocyanins, flavonoids, and probiotic activity. Combined with a three-stage temperature-controlled fermentation process, the aeration rate and pH value are precisely controlled, which increases the number of live probiotics and the retention rate of anthocyanins compared with conventional fermentation. At the same time, the particle size of different components is controlled by graded ultra-fine pulverization, which greatly increases the specific surface area and improves the dissolution rate of active ingredients compared with conventional pulverization process. Combined with the two-stage addition of prebiotics, it not only compensates for fermentation loss but also avoids component aggregation, further improving the absorption efficiency of the human body for core nutrients and active ingredients, and ensuring that the product efficacy is fully realized. (3) The present invention optimizes the formula and process to achieve a general basic and personalized precise conditioning, covering a wide range of people such as salt sensitivity, obesity-related, and elderly people with isolated systolic hypertension, solving the problem of insufficient adaptability of existing products with a one-size-fits-all approach; the product strictly follows the dietary principles of reducing sodium and increasing potassium and low GI for people with hypertension, with no added sodium or artificial additives throughout the process, high safety and good taste, improving consumption compliance. Attached Figure Description

[0018] The accompanying drawings are provided to further illustrate the invention and form part of the specification. They are used together with the embodiments of the invention to explain the invention, but do not constitute a limitation thereof. In the drawings: Figure 1 This is a schematic diagram of the preparation method of the present invention. Detailed Implementation

[0019] The following will refer to the appendices in the embodiments of the present invention. Figure 1 The technical solutions in the embodiments of the present invention are clearly and completely described herein. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0020] Example 1: The ingredients were 43% dietary fiber, 30% resistant starch, 12% prebiotics, 10% food-medicine homology, and 5% functional fortification, totaling 100%. In the dietary fiber group, the weight ratio of purple potato flour to oat bran was 3:1; the anthocyanin content of the purple potato flour was 220 mg / 100g, and the β-glucan content of the oat bran was 12%. In the resistant starch group, the weight ratio of high-resistant starch brown rice to mixed beans was 2:1; the resistant starch content of the high-resistant starch brown rice was 18%, and the mixed beans were a 1:1 mixture of black beans and chickpeas. In the prebiotic group, the weight ratio of xylooligosaccharides, inulin, and resistant dextrin was 4:2.5:1.5. In the food-medicine homology group, the weight ratio of hawthorn extract, poria cocos powder, and cassia seed extract was 3.5:2.5:1; the total flavonoid content of the hawthorn extract was 12%, the polysaccharide content of the poria cocos powder was 35%, and the total anthraquinone content of the cassia seed extract was 0.4%. In the functional enhancement group, the weight ratio of buckwheat flavonoids to mulberry leaf DNJ was 2:1.

[0021] Dietary fiber and resistant starch groups were mixed, and the moisture content was adjusted to 28%. A compound probiotic consisting of *Lactobacillus plantarum* and *Lactobacillus acidophilus* was inoculated, and fermented for 18 hours at 28°C and dissolved oxygen 1.5 mg / L to obtain the fermentation substrate. The fermentation substrate, the food-medicine homology group, and the functional fortification group were ultra-finely pulverized to D50 of 22 μm, 12 μm, and 8 μm, respectively. First, the food-medicine homology group and the functional fortification group were added to the fermentation substrate and mixed at 30 rpm and 22°C for 12 minutes to obtain a primary mixture. Then, the prebiotic group was added to the primary mixture and mixed at 15 rpm and 18°C ​​for 8 minutes to obtain a mixed powder. The inulin content was increased by 20% (120% of the original inulin ratio in step S1). The mixed powder was sterilized by irradiation and then packaged with nitrogen to obtain the product.

[0022] Product testing results: anthocyanin content 115mg / 100g, β-glucan content 6.2%, GI value 52, short-chain fatty acid precursor content 36%, butyric acid yield after 24h of in vitro simulated intestinal fermentation 7.5mg / g, beneficial intestinal bacteria (mainly Lactobacillus plantarum and Lactobacillus acidophilus) proliferation rate 210%, and active ingredient dissolution rate 65%.

[0023] Example 2: Based on the group composition ratio of Example 1 (the functional enhancement group was adjusted to 4%, the dietary fiber group to 44%, and others remained unchanged; the reason for the adjustment was to adapt to the three-stage fermentation process, ensuring that the total amount of components was 100% while not affecting the core efficacy), step S2 adopted a three-stage temperature-controlled fermentation. The dietary fiber group and the resistant starch group were mixed, the moisture content was adjusted to 28%, and a compound probiotic composed of Lactobacillus plantarum, Lactobacillus acidophilus, and Bifidobacterium lactis in a live bacteria ratio of 2.5:1.5:1 was inoculated, with a total inoculation amount of 5×106 CFU / g. The first stage activation period was 29℃, 5h, aeration rate of 0.8 vvm, and pH reduced to 5.8; the second stage proliferation period was 31℃, 9h, 0.2 vvm, and pH reduced to 5.0; the third stage stabilization period was 27℃, 4h, aeration was stopped, and the final pH was 4.8. The total fermentation time was 18h. Subsequent steps S3-S5 were the same as in Example 1.

[0024] Product testing results: anthocyanin content 118 mg / 100g, β-glucan content 6.3%, GI value 50, short-chain fatty acid precursor content 38%, butyric acid yield 9.2 mg / g after 24 hours of in vitro simulated intestinal fermentation, Bifidobacterium proliferation rate 240%, and active ingredient dissolution rate 75%. Compared with Example 1, the viable count of *Lactobacillus plantarum* increased by 32%, and by 35% compared with Comparative Example 1 (conventional isothermal fermentation); the anthocyanin retention rate increased by 15.4%, and by 28% compared with Comparative Example 1; the butyric acid yield increased by 22.7%, and the Bifidobacterium proliferation rate increased by 14.3%. This example verifies the synergistic effect of three-stage fermentation and compound probiotic formulation on gut microbiota regulation and active ingredient retention.

[0025] Example 3: Based on the proportions and strains used in Example 2, step S3 employs a low-temperature protection process. The fermentation substrate is first freeze-dried under vacuum: temperature -45℃, vacuum degree 8Pa, dried to 6% moisture content, and then transferred to an air jet mill within 3 minutes for ultra-fine pulverization to D50 22μm under nitrogen protection at 3℃. The medicinal and edible homology group is freeze-pulverized using liquid nitrogen at a pulverization temperature of -45℃. Step S4 employs a two-stage mixing process: the medicinal and edible homology group and the functional enhancement group are pre-mixed for 8 minutes to obtain a medicinal and edible functional premix; the medicinal and edible functional premix is ​​added to the fermentation substrate and mixed at 35 rpm and 23℃ for 12 minutes to obtain a primary mixture; in the first stage, xylooligosaccharides and resistant dextrin are added to the primary mixture and mixed at 20 rpm and 21℃ for 4 minutes to obtain a secondary mixture; in the second stage, inulin is added to the secondary mixture and mixed at 15 rpm and 18℃ for 3 minutes. The inulin proportion is increased by 20% in step S1 and then added in equal amounts in two stages (50% each).

[0026] Product testing results: anthocyanin content 120mg / 100g, β-glucan content 6.4%, GI value 49, short-chain fatty acid precursor content 39%, butyric acid yield 9.5mg / g after 24h of simulated intestinal fermentation, bifidobacteria proliferation rate 245%, active ingredient dissolution rate 92% (42% higher than the baseline of 65% in Example 1, and 45% higher than the conventional hot air drying process), and ACE inhibitory activity 78%. Compared with Example 2, the active ingredient dissolution rate increased by 22.7%, demonstrating the significant synergistic effect of vacuum freeze-drying, liquid nitrogen cryogenic pulverization, and two-stage mixing process on the retention and release of active ingredients.

[0027] Example 4: Based on the process of Example 3, a special five-grain powder for salt-sensitive hypertension was prepared. In step S1, 2.5% of a low-sodium salt substitute composed of potassium chloride and ammonium chloride in a weight ratio of 2:1 was added. The proportion of Poria cocos powder in the food-medicine homology group was increased to 45% (the proportions of hawthorn extract and cassia seed extract were adjusted accordingly to ensure that the total weight of the food-medicine homology group remained unchanged while increasing the proportion of Poria cocos powder, and to avoid affecting the synergistic effect of intestinal flora regulation and direct blood pressure reduction). The proportions of other groups were the same as in Example 3. In step S2, the proliferation period was extended to 11 hours (5 hours for activation, 11 hours for proliferation, and 4 hours for stability, for a total of 20 hours). Other parameters for the three-stage process were the same as in Example 3. Steps S3-S5 were the same as in Example 3.

[0028] Product testing results: Anthocyanin content 119mg / 100g, β-glucan content 6.3%, GI value 48, short-chain fatty acid precursor content 40%, butyric acid yield 9.8mg / g after 24h of in vitro simulated intestinal fermentation, Bifidobacterium proliferation rate 250%, sodium content decreased by 40% compared to Examples 1-3, and potassium content increased by 35% compared to Examples 1-3. Compared to Example 3, this example shows a 40% reduction in sodium content and a 35% increase in potassium content. In an in vitro simulated intestinal environment of salt-sensitive individuals, butyric acid yield increased by 3.2%, and Bifidobacterium proliferation rate increased by 2.1%, making it more suitable for the sodium and potassium metabolism regulation needs of salt-sensitive hypertensive individuals. This example is designed for salt-sensitive hypertension, achieving sodium-potassium balance optimization and enhanced antihypertensive efficacy through low-sodium salt substitution, increased proportion of Poria cocos, and prolonged proliferation period, verifying the effectiveness of subtype-customized technology.

[0029] Comparative Example 1: Following the proportions and mixing process of Example 1, step S2 employed conventional isothermal fermentation instead of the three-stage fermentation: temperature 30°C, time 18 hours, natural pH variation (uncontrolled), constant aeration rate of 0.5 vvm (unsegmented), and dissolved oxygen level of approximately 5-6 mg / L under natural conditions (uncontrolled ≤2 mg / L). A single *Lactobacillus plantarum* strain was inoculated (without *Lactobacillus acidophilus* or *Bifidobacterium lactis*), at an inoculation density of 5 × 10⁻⁶. 6 CFU / g. Other steps are the same as in Example 1.

[0030] Product testing results: anthocyanin content 88mg / 100g, β-glucan content 6.1%, GI value 54, short-chain fatty acid precursor content 33%, butyric acid yield after 24h of simulated intestinal fermentation 6.8mg / g, Bifidobacterium proliferation rate 165%, and active ingredient dissolution rate 58%. Compared with Example 2, the viable count of *Lactobacillus plantarum* was 32% lower, the anthocyanin retention rate was 25% lower, the butyric acid yield was 26% lower, and the Bifidobacterium proliferation rate was 31% lower; compared with Example 1, the proliferation rate of beneficial intestinal bacteria was 21.4% lower (Example 1 was 210%). This comparative example demonstrates that the lack of three-stage temperature-controlled fermentation and the compound probiotic ratio led to a significant decrease in the effect of gut microbiota regulation and an increase in the loss of active ingredients.

[0031] Comparative Example 2: Following the proportions and low-temperature pulverization process of Example 3, step S4 adopted a one-time mixing process instead of sequential mixing: the fermentation base, the food-medicine homology group, the functional enhancement group, and the prebiotic group (inulin was added according to the original proportions in step S1 without increasing the compensation amount) were simultaneously added to the mixer at a speed of 25 rpm, a temperature of 20°C, and a time of 20 min. There was no premixing or graded addition.

[0032] Product testing results: anthocyanin content 117 mg / 100g, β-glucan content 6.2%, GI value 51, short-chain fatty acid precursor content 37%, butyric acid yield after 24 hours of simulated intestinal fermentation 7.8 mg / g, bifidobacteria proliferation rate 191%, active ingredient dissolution rate 72%, mixing uniformity RSD 12% (4% in Example 3), inulin agglomeration rate 15% (measured through a 40-mesh sieve, percentage of material remaining on the sieve). Compared with Example 3, the mixing uniformity was significantly reduced (RSD 12% vs 4%), inulin agglomeration was severe, the bifidobacteria proliferation rate was 22% lower, and the active ingredient dissolution rate was 21.7% lower. This comparative example demonstrates that the lack of sequential mixing, inulin compensation, and premixing leads to decreased mixing uniformity, loss of prebiotic activity, and reduced efficacy.

[0033] Comparative Example 3: Following the proportions and mixing process of Example 3, step S3 uses conventional hot air drying and room temperature mechanical pulverization instead of the low-temperature protection process: the fermentation base material is dried with hot air at 80°C to a moisture content of 8% (a common industry process), and then mechanically pulverized at room temperature to a D50 of 22μm; the medicinal and edible homologous group is pulverized at room temperature to a D50 of 12μm. Other steps are the same as in Example 3.

[0034] Product testing results: anthocyanin content 75mg / 100g, β-glucan content 6.0%, GI value 55, short-chain fatty acid precursor content 34%, butyric acid yield after 24h of simulated intestinal fermentation 7.2mg / g, bifidobacteria proliferation rate 185%, active ingredient dissolution rate 60%, ACE inhibitory activity 59% (78% in Example 3). Compared with Example 3, the anthocyanin retention rate is 37.5% lower, the active ingredient dissolution rate is 34.8% lower, and the ACE inhibitory activity is 24.4% lower. This comparative example demonstrates that the lack of vacuum freeze-drying and liquid nitrogen cryogenic pulverization leads to a significant loss of heat-sensitive active ingredients and a significant decrease in efficacy.

[0035] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A method for preparing a multigrain powder for assisting in lowering blood pressure, characterized in that, Includes the following steps: S1: The dietary fiber group, resistant starch group, prebiotic group, food-medicine homology group, functional fortification group, and other powdered compositions are formulated according to the following weight percentages: dietary fiber group 35-50%, resistant starch group 25-35%, prebiotic group 8-15%, food-medicine homology group 5-12%, and functional fortification group 2-5%; wherein, the dietary fiber group is composed of purple potato flour and oat bran, with a weight ratio of (2-4):1; the resistant starch group is composed of high-resistant starch brown rice and mixed beans, with a weight ratio of (2-4):

1. The weight ratio is (1.5-2.5):1; the prebiotic group consists of xylooligosaccharides, inulin and resistant dextrin, with a weight ratio of (3-5):(2-3):(1-2); the food-medicine homology group consists of hawthorn extract, poria cocos powder and cassia seed extract, with a weight ratio of (3-4):(2-3):1; the functional enhancement group consists of buckwheat flavonoids and mulberry leaf DNJ in a weight ratio of (1-3):1; and the weight ratio of dietary fiber group to resistant starch group is (1.2-1.8):

1. S2: Mix the dietary fiber group and resistant starch group obtained in step S1 evenly, adjust the moisture content to 25-30%, inoculate with compound probiotics, and carry out low-temperature fermentation at 26℃-32℃ and dissolved oxygen ≤2mg / L to obtain fermentation substrate; S3: The fermentation substrate obtained in step S2, the food-medicine homology group and the functional enhancement group obtained in step S1 are subjected to ultra-fine grinding, and the particle size D50 of the fermentation substrate is controlled to be 20μm-25μm, the particle size D50 of the food-medicine homology group is 10μm-15μm, and the particle size D50 of the functional enhancement group is ≤10μm. S4: First, add the pulverized medicinal and edible homologous group and functional enhancement group to the pulverized fermentation base material, and mix for 10-15 minutes at a speed of 20-40 rpm and a temperature ≤25℃ to obtain a primary mixture; then add the prebiotic group obtained in step S1 to the primary mixture, and mix for 5-10 minutes at a speed of 10-20 rpm and a temperature ≤20℃ to obtain a mixed powder; wherein, the amount of inulin added is increased by 15-25% according to the ratio in step S1; S5: After sterilizing the mixed powder obtained in step S4, package it to obtain the blood pressure lowering five-grain powder.

2. The method for preparing a blood pressure-lowering multigrain powder according to claim 1, characterized in that, In step S1, the purple potato flour contains anthocyanin content ≥200mg / 100g, the oat bran contains β-glucan content ≥10%, the high-resistant starch brown rice contains resistant starch content ≥15%, the mixed beans are at least one of black beans and chickpeas, the hawthorn extract contains total flavonoid content ≥10%, the poria cocos powder contains polysaccharide content ≥30%, the cassia seed extract contains total anthraquinone content ≤0.5%, and the other powdered compositions in step S1 include black bean flour, soybean flour, walnut flour, millet flour, corn flour, and enzymatically hydrolyzed oat flour.

3. The method for preparing a blood pressure-lowering multigrain powder according to claim 2, characterized in that, The low-temperature fermentation described in step S2 employs a three-stage temperature-controlled fermentation process, and the pH is adjusted by controlling the aeration rate and feeding rate. The first phase is the activation period, with a temperature of 28℃-30℃, a duration of 4-6 hours, a ventilation rate of 0.5 vvm-1.0 vvm, and the pH controlled to drop to 5.5-6.

0. The second stage is the proliferation period, with a temperature of 30℃-32℃, a duration of 6h-12h, a ventilation rate reduced to 0.1vvm-0.3vvm, and a pH controlled to 4.8-5.

2. The third stage is the stabilization period, with a temperature of 26℃-28℃ and a time of 2h-6h. Aeration is stopped, and the final pH is controlled at 4.5-5.

0. The total fermentation time is 12h-24h.

4. The method for preparing a blood pressure-lowering multigrain powder according to claim 3, characterized in that, The compound probiotics mentioned in step S2 are composed of Lactobacillus plantarum, Lactobacillus acidophilus and Bifidobacterium lactis in a live bacteria ratio of (2-3):(1-2):

1.

5. The method for preparing a blood pressure-lowering multigrain powder according to claim 4, characterized in that, Before ultrafine pulverization, the fermentation substrate in step S3 is first subjected to vacuum freeze-drying: dried to a moisture content of ≤8% at -40℃ to 50℃ and a vacuum degree of ≤10Pa, and then transferred to an air jet mill within 5 minutes for ultrafine pulverization under the protection of a low-temperature inert gas at 0℃ to 5℃, controlling the particle size D50 to be 20μm to 25μm; the ultrafine pulverization of the medicinal and edible homology group in step S3 adopts liquid nitrogen freeze pulverization process with a pulverization temperature of ≤-40℃.

6. The method for preparing a blood pressure-lowering multigrain powder according to claim 5, characterized in that, Before adding the fermentation base, the medicinal and edible homology group and the functional enhancement group mentioned in step S4 are premixed for 3-10 minutes to obtain a medicinal and edible functional premix, and then the fermentation base is added. The prebiotic component mentioned in step S4 is added in two stages: In the first stage, xylooligosaccharides and resistant dextrin are added to the primary mixture and mixed for 3-5 minutes at a speed of 15-25 rpm and a temperature of ≤22℃ to obtain the intermediate mixture. In the second stage, inulin is added to the intermediate mixture and mixed for 2-5 minutes at a speed of 10-20 rpm and a temperature of ≤20℃. The inulin is added in equal amounts in two stages after the proportion of inulin is increased by 15-25% in step S1.

7. The method for preparing a blood pressure-lowering multigrain powder according to claim 6, characterized in that, When used to prepare five-grain powder for salt-sensitive hypertension, in step S1, an additional 2-3% of a low-sodium salt substitute composed of potassium chloride and ammonium chloride in a weight ratio of 2:1 is added, and the proportion of Poria cocos powder in the food-medicine homology group is increased to 40-50%; in step S2, the proliferation period is extended to 10-12 hours.

8. The method for preparing a blood pressure-lowering multigrain powder according to claim 6, characterized in that, When used to prepare multigrain powder for obesity-related hypertension, 3-5% konjac glucomannan is added in step S1, and the proportion of resistant starch is increased to 32-35%; in step S3, konjac glucomannan and fermentation base are pulverized together to a D50 of 30μm-40μm.

9. The method for preparing a blood pressure-lowering multigrain powder according to claim 6, characterized in that, When preparing a multigrain powder for treating isolated systolic hypertension in the elderly, in step S1, the proportion of xylooligosaccharides in the prebiotic group is increased to 50-60%, and vitamin K2 40-60μg / 100g powder is added additionally; in step S4, the addition is carried out in stages, first 50% of xylooligosaccharides are mixed with the primary mixture, and the remaining 50% is added together with inulin during the second stage of prebiotic addition.

10. A multigrain powder for assisting in lowering blood pressure, characterized in that, It is prepared by the preparation method according to any one of claims 1-9; the anthocyanin content in the grain powder is ≥100mg / 100g, the β-glucan content is ≥5%, and the GI value is ≤55.